Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2003

View Archived Issues

Company Profile: Adventrx Pharmaceuticals

Melatonin as a novel therapy for Alzheimer's disease

Beta-L-2'-Fd4C shows antiviral activity and favorable pharmacokinetics in HBV

Sulphamoylated estrogen derivatives show potential in treating drug-resistant breast cancer

Yamanouchi and GlaxoSmithKline to copromote Vesicare in U.S.

Enrollment opens in phase II trial of Tarceva in malignant glioma

Phase II trial preparations advance for Norwood Immunology technology

Incara selects AEOL-10150 as candidate for ALS

FDA approves Trileptal for children

Paratek claims non-antibacterial tetracyclines for cancer, stroke and lung injury

Novel antibacterial tetracyclines in Paratek development pipeline

Receptor tyrosine kinase inhibitors and their use reported by Theravance

Novel 5-HT2C receptor ligands and their use as antiobesity agents

Novel series of Syk kinase inhibitors covered by Boehringer Ingelheim patent

Phase II DCF-987 trial completes enrollment

Ceregene acquires rights to ALS gene therapy from Salk Institute

ViroPharma acquires maribavir rights from GlaxoSmithKline

FDA Advisory Committee schedules review of Metvix for basal cell carcinoma

SGN-35 selectively targets CD30-positive malignancies in models of Hodgkin's disease

Caprion and AstraZeneca collaborate on pain biomarker research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...